Examples of medicinal products that may increase haloperidol plasma concentrations based on clinical experience or drug interaction mechanism include: The results are within the observed variability in haloperidol pharmacokinetics. Haloperidol can increase the CNS depression produced by alcohol or CNS-depressant medicinal products, including hypnotics, sedatives or strong analgesics. There was a trend toward shorter half-lives in children compared to adults. Haloperidol may antagonise the effect of levodopa and other dopamine agonists. If concomitant treatment with an antiparkinson medicinal product is required, it may have to be continued after stopping HALDOL if its excretion is faster than that of haloperidol in order to avoid the development or aggravation of extrapyramidal symptoms. Hypotension and circulatory collapse may be counteracted by use of intravenous fluids, plasma or concentrated albumin and vasopressor agents, such as dopamine or noradrenaline.
|Date Added:||7 July 2013|
|File Size:||69.70 Mb|
|Operating Systems:||Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X|
|Price:||Free* [*Free Regsitration Required]|
Reduced CYP2D6 enzyme activity may result in increased concentrations of haloperidol.
Haldol 2mg/ml oral solution
Vomiting Nausea Constipation Dry mouth Salivary hypersecretion. Adverse reaction frequencies are based on or estimated from clinical trials or epidemiology studies with haloperidol, and classified using the following convention: These tumours may be caused by prolonged dopamine D2 antagonism and hyperprolactinaemia.
No dose adjustment is recommended, but caution is advised when treating patients with renal impairment. Paediatric population Available safety data in the paediatric population indicate a risk of developing extrapyramidal symptoms, including tardive dyskinesia, and sedation.
Although no clear association with the administration of antipsychotics and human breast tumours has been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history.
A baseline ECG is recommended before treatment. The activity on the basal ganglia probably underlies the undesirable extrapyramidal motor effects dystonia, akathisia and parkinsonism.
Treatment of mild to moderate chorea in Huntington’s disease, when other medicinal products are ineffective or not tolerated. Caution is recommended when haloperidol is halopreidol to patients manifesting hypotension or orthostatic hypotension. Haloperidol elevates prolactin level. Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Haloperidol crosses the blood-brain barrier easily. The safety and efficacy of HALDOL oral solution in children below the ages defined halpoeridol the indications have not been established. Haloperidol apparent clearance after extravascular administration ranges from 0. OR Child resistant, polypropylene screw-cap with low density polyethylene insert.
A subset of patients may require higher concentrations as a consequence of a high inter-subject variability in haloperidol pharmacokinetics.
Ventricular fibrillation Torsade de pointes Ventricular tachycardia Extrasystoles. Acute treatment of delirium when non-pharmacological treatments have failed.
Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www. Blood and lymphatic system disorders.
Pancytopenia Agranulocytosis Thrombocytopenia Neutropenia. Antagonism of the effect of the anticoagulant phenindione has been reported.
These studies included mainly children and adolescents aged between 2 and 17 years.
Haldol 2mg/ml oral solution – Summary of Product Characteristics (SmPC) – (eMC)
Thyroxin may facilitate haloperidol toxicity. Renal and urinary disorders. Other forms of interaction In rare cases the following symptoms were reported during the concomitant use of lithium and haloperidol: Haloperidol is an inhibitor of CYP2D6. There is a high inter-subject variability for plasma protein binding.
Medicinal products that may increase haloperidol plasma concentrations Haloperidol is metabolised by several routes see section 5. Metabolic and nutritional disorders. Males and younger age groups are at higher risk of experiencing such reactions.
Photosensitivity reaction Urticaria Pruritus Hyperhidrosis. Pharmacodynamic effects Haloperidol suppresses delusions and hallucinations as a direct consequence of blocking dopaminergic signalling in the mesolimbic pathway. Increased haloperidol plasma concentrations may result in an increased risk of adverse events, including QTc-prolongation see section 4.